dimemorfan dimemorfan dimemorfan (inn) (or dimemorphan) (brand names astomin, dastosirr, tusben), or dimemorfan phosphate (jan), also known as 3,17-dimethylmorphinan, is an antitussive (cough suppressant) of the morphinan family that is widely used in japan and is also marketed in spain and italy. it was developed by yamanouchi pharmaceutical (now astellas pharma) and introduced in japan in 1975. it was later introduced in spain in 1981 and japan in 1985. dimemorfanclinical datatrade namesastomin, datosin, gentusahfs/drugs.cominternational drug namesatc coder05da11 (who) identifiers iupac name (4bs,8as,9s)-3,11-dimethyl-6,7,8,8a,9,10-hexahydro-5h-9,4b-(epiminoethano)phenanthrene cas number36309-01-0 ypubchem cid3037918chemspider16735785 yunii623oac38yukeggd07848 ychemblchembl2106325 necha infocard100.048.134 chemical and physical dataformulac18h25nmolar mass255.405 g·mol−13d model (jsmol)interactive image smiles cc1=cc2=c(c3n(cc42cccc34)c)c=c1 inchi inchi=1s/c18h25n/c1-13-6-7-14-12-17-15-5-3-4-8-18(15,16(14)11-13)9-10-19(17)2/h6-7,11,15,17h,3-5,8-10,12h2,1-2h3/t15-,17+,18+/m1/s1 ykey:kbezzlaakiipfk-njafhuggsa-n y ny (what is this?) (verify) side effects adverse effects include nausea, somnolence, dry mouth, and decreased appetite. pharmacology dimemorfan is an analogue of dextromethorphan (dxm) and its active metabolite dextrorphan (dxo), and similarly to them, acts as a potent agonist of the σ1 receptor (ki = 151 nm). however, unlike dxm and dxo, it does not act significantly as an nmda receptor antagonist (ki = 16,978 nm), and for this reason, lacks dissociative effects, thereby having reduced side effects and abuse potential in comparison. similarly to dxm and dxo, dimemorfan has only relatively low affinity for the σ2 receptor (ki = 4,421 nm).